Form 4: Cidara Therapeutics Director James Merson Acquires Stock Options
SEC Form 4 Filing
Director James Merson acquired stock options in Cidara Therapeutics, Inc. on July 18, 2024.
Summary
- On July 18, 2024, James Merson, a director of Cidara Therapeutics, Inc., acquired 2,125 stock options at an exercise price of $12.64.
- These options vest on the earlier of the first anniversary of the grant date or the day before the Issuer's 2025 annual meeting of stockholders.
- Following the transaction, Merson directly owns 2,125 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of stock options, which can be seen as a sign of confidence, but doesn't provide enough information to strongly influence sentiment.
Positives
- The acquisition of stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 07/18/2024 | Date of transaction: James Merson acquired stock options. |
| 07/19/2024 | Date of signature by Attorney-in-Fact. |
| 07/17/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.